uniQure the winner among trio of rare neuro readouts: Clinical Report

uniQure was the big mover of the week, more than tripling in value, after its gene therapy improved functional outcomes in a Huntington’s disease study. Meanwhile, two other companies reported clinical misses in rare neurological indications: Acadia in Prader-Willi syndrome and Harmony Biosciences in Fragile X.

Data released Wednesday drove shares of uniQure N.V. (NASDAQ:QURE) up 248%, as the biotech’s AMT-130 met the primary endpoint in the pivotal Phase I/II study. The stock move lifted the biotech’s market cap to a four-year high, topping $2.6 billion at the close...